You're signed outSign in or to get full access.
Exor Capital LLP
Exor Capital LLP is an investment management firm based in London, United Kingdom. Exor Capital manages significant public equity portfolios, notably on behalf of its parent, Exor NV—one of Europe's largest diversified holding companies, rooted in the Italian Agnelli family legacy. The firm manages investments across multiple sectors with a global mandate and is an institutional investor registered with the U.S. SEC. Exor Capital and its affiliate companies employ teams who leverage research and long-term, value-oriented strategies to invest in public markets; employee count specific to Exor Capital LLP is not published but the parent group employs hundreds globally.
Investment Strategy
Exor Capital LLP focuses on concentrated, long-term investments in public equities, favoring businesses with strong, sustainable competitive advantages and sound governance. The strategy seeks to achieve superior risk-adjusted returns by leveraging deep fundamental research and patient capital, closely aligned with the investment philosophy and values of its parent, Exor NV. The firm tends to invest across geographies and industries, often holding significant minority stakes in companies with potential for growth and value creation, reflecting the entrepreneurial tradition of the Agnelli family.
Latest 13F Filing Activity
Exor Capital LLP filed their most recent 13F report on Jun 30, 2025 disclosing 42 equity positions and 3 options positions with a total 13F market value of $5B. The fund increased holdings in Carvana Co., Paramount Global, Novagold Res Inc. among other positions. Exor Capital LLP reduced exposure to Harmony Gold Mining Co. LTD, Schlumberger LTD, Procore Technologies Inc. among others.
Top Holdings
Equity Positions (42)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
C CVNA | CARVANA CO | 26.97% | $1.27B | 3,765,251 | $23.11 | $336.96 | +$422.9M |
P PARA | PARAMOUNT GLOBAL | 14.00% | $658.4M | 51,040,940 | $11.05 | $12.90 | +$110.3M |
T TEVA | TEVA PHARMACEUTICAL INDS LTD | 10.03% | $471.9M | 28,156,918 | $9.34 | $16.76 | +$43.8M |
R RRC | RANGE RES CORP | 6.19% | $291.3M | 7,161,614 | $15.04 | $40.67 | +$10.8M |
V VEON | VEON LTD | 5.83% | $274.5M | 5,957,666 | $19.81 | $46.07 | +$17.7M |
Options Positions (3)
Industry Allocation
Investment Team (14)
| Name | Role | Location | |
|---|---|---|---|
 | Managing Director | United States | |
A Amanda Collin | Business Analyst | United States | |
 | Partner | Paris, France | |
 | Equity Investments Analyst | London, United Kingdom | |
 | Investment Analyst | London, United Kingdom | |
E Erion Bregu | Principal | United Kingdom | |
G Giuseppe Buccoliero | Investment Associate | London, United Kingdom | |
 | Investment Analyst | United Kingdom | |
M Maite Trenchs | Principal - Head of Corporate Finance and IR | Amsterdam, NH , The Netherlands | |
 | Managing Director | Milan, Italy |
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more